Tetrahydrobiopterin as a Treatment for Autism Spectrum Disorders: A Double-Blind, Placebo-Controlled Trial
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The purpose of this study was to determine if tetrahydrobiopterin (BH4) reduced core symptoms of autism spectrum disorder (ASD). METHOD: In this study, 46 children, 3-7 years of age diagnosed with an ASD were randomly assigned to double-blind treatment with 20 mg/kg/day BH4 or placebo for 16 weeks. The primary outcome measure was the Clinical Global Impressions Improvement and Severity Scales (CGI-I and CGI-S); secondary outcomes were the Preschool Language Scale-4 (PLS-4), Social Responsiveness Scale (SRS), Aberrant Behavior Checklist (ABC), and Vineland Adaptive Behavior Scales (Vineland). RESULTS: Overall, no differences were found on global improvement as measured with the CGI-I or CGI-S. Secondary measures indicated significant improvements for BH4 relative to placebo with regard to social awareness, autism mannerisms, hyperactivity, and inappropriate speech. Side effects were minimal and similar between both active medication and placebo. CONCLUSIONS: These results indicate that BH4 offers promise in reducing symptoms of ASD. Clinical Trials.gov Identifier: NCT00850070.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
A Systematic Review of Early Intensive Intervention for Autism Spectrum Disorders
Warren, Z., McPheeters, M. L., Sathe, N., Foss-Feig, J. H., Glasser, A., & Veenstra-VanderWeele, J. (2011) · Pediatrics · doi:10.1542/peds.2011-0426 · Cited by 790
(2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1266 · Cited by 521
Behavioral treatments in autism spectrum disorder: what do we know?
Vismara, L. A., & Rogers, S. J. (2010) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.121208.131151 · Cited by 376 · cited 1×
“To date, some behavioral treatments can increase social and communicative abilities and decrease repetitive behaviors (Vismara and Rogers 2010; Warren et al. 2011).”
Cited by
Vitamin D hormone regulates serotonin synthesis. Part 1: Relevance for autism
Patrick, R. P., & Ames, B. N. (2014) · The FASEB Journal · doi:10.1096/fj.13-246546 · Cited by 414
An update on pharmacotherapy for autism spectrum disorder in children and adolescents
Ji, N. Y., & Findling, R. L. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000132 · Cited by 217
Complementary and Alternative Therapies for Autism Spectrum Disorder
Brondino, N., Fusar-Poli, L., Rocchetti, M., Provenzani, U., Barale, F., & Politi, P. (2015) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2015/258589 · Cited by 116
Frye, R. E., & Rossignol, D. A. (2016) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s38337 · Cited by 96
Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis
Fraguas, D., Díaz-Caneja, C. M., Pina-Camacho, L., Moreno, C., Durán-Cutilla, M., Ayora, M., González-Vioque, E., de Matteis, M., Hendren, R. L., Arango, C., et al. (2019) · PEDIATRICS · doi:10.1542/peds.2018-3218 · Cited by 80
Metadata
- Authors
- Klaiman, C., Huffman, L., Masaki, L., & Elliott, G. R.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2013-06
- Volume
- 23
- Issue
- 5
- Pages
- 320-328
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2061205980
- Cited by
- 63
- References
- 5
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tetrahydrobiopterin as a Treatment for Autism Spectrum Disorders: A Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1089/cap.2012.0127
- The paper
- Klaiman, C., Huffman, L., Masaki, L., & Elliott, G. R. (2013). Tetrahydrobiopterin as a Treatment for Autism Spectrum Disorders: A Double-Blind, Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2012.0127
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.